More recently, molecular studies have identified new targeted options and suggested that involvement of the PD-1/PD-L1 [9] and HLA-E/NKG2A [10,11] pathways could represent major therapeutic targets to restore immune system function and enhance anti-tumor responses. The gene discussed is KLRC1; the disease is neoplasm.